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Direct inhibitory effects of simvastatin on matrix accumulation that the amelioration of hypercholesterolemia has bene-
in cultured murine mesangial cells. ficial effects on the progression of glomerular injury [1].
Background. 3-Hydroxy-3-methylglutaryl coenzyme A (HMG- Among various methods to ameliorate hypercholesterol-CoA) reductase inhibitors have been demonstrated to suppress
emia, 3-hydroxy-3-methyl-glutaryl coenzyme A (HMG-glomerular injuries in various renal diseases. These agents inhibit
CoA) reductase inhibitors have been reported to im-in vitro proliferation of several cell types, including mesangial
cells. This effect indicates the ability to ameliorate mesangio- prove albuminuria and glomerulosclerosis in experimen-
proliferative lesions, independent of the improvement of hy- tal animals [2]. The beneficial effects of these agents may
percholesterolemia. On the other hand, it is not clear whether be attributed to their ability to reduce the circulatingHMG-CoA reductase inhibitors directly regulate extracellular
levels of low-density lipoprotein (LDL), which stimu-matrix (ECM) accumulation from mesangial cells.
lates mesangial cell proliferation and matrix protein ac-Methods. In this study, to examine the in vitro effects of
simvastatin, an HMG-CoA reductase inhibitor, on mRNA ex- cumulation or those of oxidized LDL, which exhibits
pressions of matrix proteins, growth factors, and matrix turn- cytotoxic effects on mesangial cells [3]. On the other
over proteins, we incubated cultured murine mesangial cells hand, recent studies have shown in vitro effects of thesestimulated by fetal calf serum (FCS) with or without simva-
agents on several cell types, including mesangial cells. Instatin for 24 hours, and Northern analysis was performed.
human glomerular mesangial cells, simvastatin inhibitsResults. Simvastatin showed a slightly suppressive effect on
mRNA expression of type IV collagen and fibronectin and a platelet-derived growth factor (PDGF)-induced DNA
slightly up-regulative effect on that of type I collagen, whereas synthesis in a dose-dependent manner [4]. Lovastatin
mRNA expression of type III collagen was markedly up-regu- suppresses mRNA expression of monocyte chemoattrac-lated. mRNA expression of platelet-derived growth factor
tant protein-1 (MCP-1) in cultured mesangial cells [5].(PDGF)-B chain and PDGF receptor b-subunit was sup-
These findings demonstrate that HMG-CoA reductasepressed, whereas that of transforming growth factor-b (TGF-b)
was not affected by simvastatin. Concerning matrix turnover inhibitors directly suppress proliferative and inflamma-
proteins, simvastatin markedly reduced mRNA expression of tory glomerular lesions, independent of cholesterol re-
plasminogen activator inhibitor-1 (PAI-1) without affecting the duction; however, their direct effect on glomerular ma-expression of tissue-type plasminogen activator (tPA).
trix expansion has not been clearly demonstrated. ToConclusion. These results suggest type-specific modulation
elucidate the direct relationship between HMG-CoA re-of matrix protein production independent of TGF-b and the
suppressive effects of autocrine PDGF by administration of ductase inhibitors and the tissue repair and/or sclerotic
HMG-CoA reductase inhibitors in mesangial cells. Moreover, mechanism, we examined the effects of simvastatin on
the beneficial effects of these agents on matrix protein accumu- the expression of growth factors, extracellular matrix
lation may be through promoting ECM degradation derived
(ECM) proteins, and matrix turnover proteins, includingfrom PAI-1 suppression.
plasminogen activators and plasminogen activator inhi-
bitor-1 (PAI-1), in cultured murine mesangial cells.
Much attention has been directed toward the patho-
genic role of cholesterol in glomerular injury and the METHODS
relationship between glomerular sclerosis and athero- Murine mesangial cell culture
sclerosis. Several studies, including our own, have shown
Twenty-four-week-old BALB/c mice were sacrificed,
and the kidneys were removed in a sterile manner. Glo-
merular mesangial cells were cultured according to theKey words: extracellular matrix, platelet-derived growth factor, plas-
minogen activator inhibitor-1. methods of MacKay et al [6]. Cells obtained from pas-
sages 5 to 12 were used for the experiments. 1999 by the International Society of Nephrology
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Simvastatin and mevalonate preparation
Simvastatin salt was kindly provided by Banyu Phar-
maceutical Co., Ltd. (Tokyo, Japan) and was prepared
as described by Kita et al [7]. Mevalonic acid lactone was
prepared as described by O’Donnell et al [8]. Aliquots of
these solutions were stored at 2208C until use.
RNA purification and Northern analysis
Preconfluent mesangial cells were cultured in fibro-
nectin-coated 100 mm dishes for 48 hours in serum-free
modified Eagle’s medium (MEM)/F12 medium (GIBCO
BRL, Gaithersburg, MD, USA) to render the cells quies-
cent and were then further cultured for 24 hours in MEM/
F12 medium with the following additions: 10% fetal calf
serum (FCS) only, as a control; 10% FCS and 20 mm of
simvastatin; and 10% FCS, 20 mm of simvastatin, and
100 mm of mevalonate. Total RNA of cultured mesangial
cells was purified by the acid guanidium thiocyanate-
phenol-chloroform method, and Northern blot analysis
was performed as previously described [9]. Each lane of
the autoradiographs was analyzed with BAS-2000 (Fuji
film, Tokyo, Japan), and the signal densities of each
mRNA, corrected using that of GAPDH, were com-
pared among the conditions mentioned earlier here. The
expression of the following mRNA was examined: matrix
proteins such as collagen type I (a1), type III (a1), type
IV (a1), and fibronectin; growth factors such as PDGF-B
chain, PDGF-receptor b-subunit (PDGF-Rb), and trans-
forming growth factor-b (TGF-b); and matrix turnover
proteins such as matrix metalloproteinase 2 (MMP-2),
tissue-type plasminogen activator (tPA), urokinase-type
plasminogen activator (uPA), and PAI-1.
RESULTS
Simvastatin slightly suppressed mRNA expression of
collagen IV and fibronectin and slightly up-regulated
Fig. 1. Northern blot analysis of cultured murine mesangial cells. Eachthat of collagen I; however, a marked increase in collagen lane contains 10 mg of total RNA. Lane 1, control 10% fetal calf serum
III mRNA expression was noted. mRNA expression of (FCS) MEM medium; lane 2, 10% FCS MEM medium containing
20 mm simvastatin; lane 3, 10% FCS MEM medium containing 20 mmPDGF-B chain and PDGF-Rb was markedly suppressed
simvastatin and 100 mm mevalonate.in contrast to no influence on TGF-b mRNA expression.
Among the matrix turnover proteins, although MMP-2
and tPA showed no significant changes in gene expres-
and interleukin-4 [10, 11]. Considering that the in vitrosion, uPA and PAI-1 mRNA expression was significantly
synthesis of type I and III collagens was enhanced inreduced by simvastatin. The nearly complete elimination
cultured mesangial cells and that of type IV collagenof these effects by the addition of mevalonate indicates
was up-regulated in vivo, the signaling pathway affectedthe direct influence of simvastatin on these parameters
by simvastatin for these matrix protein syntheses may(Fig. 1 and Table 1).
be completely different.
Grandaliano et al reported that under PDGF-induced
DISCUSSION conditions, simvastatin did not influence mRNA expres-
These results show type-specific regulation of matrix sion of PDGF-B chain, although simvastatin completely
protein synthesis of mesangial cells by simvastatin. The inhibited up-regulated DNA synthesis induced by PDGF
distinction between the regulation of type III and type stimulation [4]. In contrast, we detected marked suppres-
sion of PDGF expression in murine mesangial cells byIV collagens was also demonstrated by cyclosporin A
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Table 1. Densitometric analysis of RNA expression protein kinase C (PKC) [13]. The remarkably differential
action of simvastatin on the expression of PAs may re-Simvastatin 20 mm
Simvastatin 20 mm Mevalonate 100 mm flect its lack of effect on PKC activity [4]. As it has been
Collagen I 134 118 reported that the physiological role of tPA is predomi-
Collagen III 244 88.2 nant to that of uPA [14] and that tPA deficiency exacer-
Collagen IV 80.5 205
bates experimental glomerulonephritis lesions to aFibronectin 84.5 138
PDGF-B chain 29.3 75.0 greater extent than uPA deficiency [15], the absence of
PDGF-Rb 60.7 92.7 an effect on tPA expression indicates that simvastatin
TGF-b 104 103
may not disturb serine proteinase activity at least in theMMP-2 92.6 98.5
tPA 106 151 glomerulus. In addition, the marked down-regulation of
uPA 18.7 75.0 PAI-1 expression may contribute beneficial effects on
PAI-1 17.9 36.2
glomerular lesions in spite of uPA down-regulation. This
Each mRNA expression was corrected using that of GAPDH. Data are shown may be an additional mechanism by which HMG-CoAas relative % of control 10% FCS medium. Abbreviations are: PDGF, platelet-
derived growth factor; TGF, transforming growth factor; MMP, matrix metallo- reductase inhibitors improve renal disease.
proteinase; tPA, tissue-type plasminogen activator; uPA, urokinase-type plas- In summary, simvastatin modulates ECM productionminogen activator; PAI-1, plasminogen activator inhibitor-1.
in a type-specific manner independent of TGF-b and
inhibits cell growth in part through the suppressive ef-
fects of autocrine PDGF. Moreover, simvastatin sup-
presses PAI-1 expression with the steady expression ofsimvastatin, along with complete suppression of DNA
synthesis under FCS-stimulated conditions (data not tPA in mesangial cells. Part of the beneficial effects of
HMG-CoA reductase inhibitors in renal diseases may beshown), as seen by Grandaliano’s group. Considering
the difference between these two studies in the condi- through its effect on ECM by enhancing matrix protein
degradation.tions that induced up-regulated cell proliferation, sim-
vastatin may inhibit some FCS-induced pathway(s) other
Reprint requests to Eri Muso, M.D., Department of Cardiovascular
than that of PDGF, which induces the expression for Medicine, Kyoto University, Graduate School of Medicine, 54 Kawara-
cho, Shogoin, Sakyo-ku, Kyoto 606-8397, Japan.mRNA of PDGF-B and its receptor. This is supported
E-mail: muso@kuhp.kyoto-u.ac.jpby a report of human fibroblasts in which lovastatin has
suppressed a signaling response to PDGF less intensely
than to epidermal growth factor (EGF) or insulin-like
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